Brief: aTyr Pharma Announces Alignment With FDA On Phase 3 Study Of Efzofitimod In Pulmonary Sarcoidosis
24/09/2026 11:01
BRIEF-aTyr Pharma Announces Alignment With FDA On Phase 3 Study Of Efzofitimod In Pulmonary Sarcoidosis Sept 24 (Reuters) - aTyr Pharma Inc ATYR.O:
ATYR PHARMA ANNOUNCES ALIGNMENT WITH FDA ON PHASE 3 STUDY OF EFZOFITIMOD IN PULMONARY SARCOIDOSIS
ATYR PHARMA - TO INITIATE STUDY-RELATED ACTIVITIES IN Q4 2026
Source text: ID:nGNX26TR3V
Further company coverage: ATYR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on aTyr Pharma
See all newsBrief: Atyr Pharma Announces Research Collaboration With Montefiore Einstein
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry
aTyr rises as FDA aligns on late-stage lung disease study plan